# Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

> **NCT00783926** · PHASE1 · COMPLETED · sponsor: **Alachua Government Services, Inc.** · enrollment: 422 (actual)

## Conditions studied

- Influenza
- Pandemic Influenza

## Interventions

- **BIOLOGICAL:** H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)

## Key facts

- **NCT ID:** NCT00783926
- **Lead sponsor:** Alachua Government Services, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-02
- **Final completion:** 2009-07
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2015-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783926, "Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00783926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*